Trial · NCT05050305
Marizomib Central Nervous System (CNS)
NCT05050305, Phase 2, Withdrawn, Dana-Farber Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Marizomib Central Nervous System (CNS). Trials, record NCT05050305. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05050305
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Marizomib Central Nervous System (CNS)
- NCT number
- NCT05050305
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Marizomib, Pomalidomide, Dexamethasone
- First posted
- 2021-09-20
- Last updated
- 2024-07-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) Safety Run-In | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | MTD is defined as the highest dose level where no patients (of the 6 treated) develop a dose limiting toxicity (DLT) |
| Primary | Dose Limiting Toxicity (DLT) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | Toxicity summaries will be stratified by dose level, grade, and treatment attribution |
| Primary | The number and proportion of adverse events, graded as defined by CTCAE version 5.0. | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | CTCAE version 5.0. |
| Primary | Overall response rate (ORR) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). |
| Secondary | Time to response (TTR) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). |
| Secondary | Progression free survival (PFS) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first. up to 5 years | Assessed using the updated International Myeloma Working Group Response Criteria |
| Secondary | Duration of response (DOR) | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years | Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). |
| Secondary | Overall survival (OS) | From date of enrollment until date of death from any cause, up to 5 years | Assessed using the updated International Myeloma Working Group Response Criteria |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05050305
GET https://conductscience.org/api/trials/v1/NCT05050305/registered